Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis



      The role of antisecretory drugs for the prevention of upper gastrointestinal bleeding in patients using anticoagulants is unclear. We investigated this question in a systematic review and meta-analysis.


      We searched Embase, PubMed, Web of Science, Scopus, the Cochrane Library, and thru April 2021 for controlled randomized trials and observational studies evaluating the association of proton pump inhibitors (PPIs) or H2-receptor antagonists with overt upper gastrointestinal bleeding in patients using anticoagulants. Independent duplicate review, data extraction, and risk of bias assessment were performed. Observational studies were included only if they provided results controlled for at least 2 variables. Meta-analyses were performed using random effects models.


      Six observational studies and 1 randomized trial were included. All but 1 study had low risk of bias. None of the studies excluded patients with concomitant aspirin or nonsteroidal anti-inflammatory drug use. For PPIs, the pooled relative risk of upper gastrointestinal bleeding was 0.67 (95% confidence interval 0.61, 0.74) with low statistical heterogeneity (I2 = 15%). Individual studies showed greater treatment effect in patients with higher risk for upper gastrointestinal bleeding (eg, nonsteroidal anti-inflammatory drug or aspirin use, elevated bleeding risk score). A single observational study evaluating the association of H2-receptor antagonists with upper gastrointestinal bleeding found a relative risk of 0.69 (95% confidence interval 0.24-2.02).


      Evidence drawn mostly from observational studies with low risk of bias demonstrate that PPIs reduce upper gastrointestinal bleeding in patients prescribed oral anticoagulants. The benefit appears to be most clearcut and substantial in patients with elevated risk of upper gastrointestinal bleeding.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barnes GD
        • Lucas E
        • Alexander GC
        • Goldberger ZD.
        National trends in ambulatory oral anticoagulant use.
        Am J Med. 2015; 128: 1300-1305.e2
        • Ho KH
        • van Hove M
        • Leng G.
        Trends in anticoagulant prescribing: a review of local policies in English primary care.
        BMC Health Serv Res. 2020; 20: 1-8
        • Smith M
        • Wakam G
        • Wakefield T
        • Obi A.
        New trends in anticoagulation therapy.
        Surg Clin North Am. 2018; 98: 219-238
        • Lamberts M
        • Staerk L
        • Olesen JB
        • et al.
        Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients.
        J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2017; 6e004517
        • Rodríguez LAG
        • Lin KJ
        • Hernández-Díaz S
        • Johansson S.
        Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications.
        Circulation. 2011; 123: 1108-1115
        • Hippisley-Cox J
        • Coupland C.
        Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.
        BMJ. 2014; 349: g4606
        • Scally B
        • Emberson JR
        • Spata E
        • et al.
        Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
        Lancet Gastroenterol Hepatol. 2018; 3: 231-241
        • Chan FK
        • Leung W.
        Peptic-ulcer disease.
        Lancet. 2002; 360: 933-941
        • Desai J
        • Kolb JM
        • Weitz JI
        • Aisenberg J.
        Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies.
        Thromb Haemost. 2013; 110: 205-212
        • Vaduganathan M
        • Bhatt DL.
        Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem.
        Clin Gastroenterol Hepatol. 2017; 15: 691-693
        • Thomopoulos KC
        • Mimidis KP
        • Theocharis GJ
        • Gatopoulou AG
        • Kartalis GN
        • Nikolopoulou VN.
        Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: Endoscopic findings, clinical management and outcome.
        World J Gastroenterol. 2005; 11: 1365-1368
        • Pourafkari L
        • Ghaffari S
        • Zamani N
        • et al.
        Upper gastrointestinal bleeding in the setting of excessive warfarin anticoagulation: Risk factors, and clinical outcome.
        Cor Vasa. 2017; 59: e128-e133
      1. Kurlander J, Fisher A, Gonzalez J, et al. Review protocol: The effect of anti-secretory agents on upper gastrointestinal bleeding risk for patients using oral anticoagulants: a systematic review. Available at: Accessed January 14, 2021.

      2. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: Accessed May 15, 2019.

        • Sterne JAC
        • Savović J
        • Page MJ
        • et al.
        RoB 2: a revised tool for assessing risk of bias in randomised trials.
        BMJ. 2019; 366: l4898
        • Lanas Á
        • Carrera-Lasfuentes P
        • Arguedas Y
        • et al.
        Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants.
        Clin Gastroenterol Hepatol. 2015; 13: 906-912.e2
      3. Lee, SR., Kwon, S., Choi, EK. et al. Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovasc Drugs Ther (2021). Accessed December 15, 2021.

        • Moayyedi P
        • Eikelboom JW
        • Bosch J
        • et al.
        Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial.
        Gastroenterology. 2019; 157: 403-412.e5
      4. Confidence Interval for a Rate Difference. Available at: ComparingFrequencies/PH717_ComparingFrequencies12.html. Accessed July 12, 2021.

        • Chandler J
        • Cumpston M
        • Li T
        • Page MJ
        • Welch VA.
        Cochrane Handbook for Systematic Reviews of Interventions.
        2nd ed. Wiley-Blackwell, Hoboken, NJ2019: 1-728
        • Page MJ
        • McKenzie JE
        • Bossuyt PM
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        BMJ. 2021; 372: n71
        • Lin KJ
        • Hernández–Díaz S
        • García Rodríguez LA
        Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.
        Gastroenterology. 2011; 141: 71-79
        • Ray WA
        • Chung CP
        • Murray KT
        • et al.
        Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding.
        JAMA. 2018; 320: 2221-2230
        • Ray WA
        • Chung CP
        • Murray KT
        • et al.
        Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding.
        Gastroenterology. 2016; 151 (e10): 1105-1112
        • Maruyama K
        • Yamamoto T
        • Aoyagi H
        • et al.
        Difference between the upper and the lower gastrointestinal bleeding in patients taking nonvitamin K oral anticoagulants.
        BioMed Res Int. 2018; 20187123607
      5. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 77(5):629-658. 10.1016/j.jacc.2020.09.011.

        • Lanza FL
        • Chan FKL
        • Quigley EMM.
        Guidelines for prevention of NSAID-related ulcer complications.
        Am J Gastroenterol. 2009; 104: 728-738
        • Lee TC
        • McDonald EG.
        Deprescribing proton pump inhibitors: overcoming resistance.
        JAMA Intern Med. 2020; 180: 571-573
        • Barkun AN
        • Almadi M
        • Kuipers EJ
        • et al.
        Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group.
        Ann Intern Med. 2019; 171: 805-822
        • Tomaselli GF
        • Mahaffey KW
        • Cuker A
        • et al.
        2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants.
        J Am Coll Cardiol. 2020; 76: 594-622
      6. Frost J, Campos-Outcalt D, Hoelting D, et al. Pharmacologic management of newly detected atrial fibrillation updated clinical practice guideline; Updated Clinical Practice Guideline 2017. Available at: Accessed October 26, 2021.